Expression and clinical significance of SERPINA5 in prostate cancer based on TCGA database

Objective To study the differential expression of pivotal genes in prostate cancer, and to provide a new biological therapeutic target and theoretical basis for the treatment of prostate cancer.

Methods The gene data related to prostate cancer were downloaded from The Cancer Genome Atlas(TCGA).The genes differentially expressed in prostate cancer tissues and para-cancer tissues were selected using R software and enrichment analysis was performed.The interaction network diagram of the proteins expressed by the differential genes was constructed using STRING 11.0, and the Hub gene was further selected through Cytoscape_v3.7.1.The expression of the Hub gene in prostate cancer was verified by Oncomine database to obtain the pivotal genes.The statistical analysis of the pivotal genes and clinical data was then performed using R software.Finally, the survival analysis of the pivotal genes was performed using online tool GEPIA.

Results A total of 551 samples(including 52 adjacent tissue samples and 499 cancer tissue samples) were obtained, and 463 differential genes were obtained after selection, among which 265 genes showing an upward trend and 198 genes showing a downward trend were obtained.After enrichment analysis, it was found that these genes were most enriched in the regulation of acrosome reaction, triglyceride metabolism process and PPAR signaling pathway.After further screening, 10 Hub genes were obtained, which were verified together with the Oncomine database to obtain the key gene SERPINA5.Clinical analysis showed that the expression level of SERPINA5 in patients with prostate cancer was related to tumor differentiation, TNM stage and disease-free survival rate(P < 0.05).and was not related to age, race, and overall survival rate(P>0.05).

Conclusions There are many differential genes in prostate cancer that may affect the occurrence and development of the disease.Among them, SERPINA5 may be used as a marker for early screening of prostate cancer or a biological target for treatment, which brings new options and research directions for the prevention and treatment of prostate cancer.